Clinical trials: B7-H3-positive Relapsed/ Refractory Neuroblastoma, open to volunteers
B7-H3-positive Relapsed/ Refractory Neuroblastoma
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
Phase I clinical trials are designed as open-label, dose-escalation and dose-expansion clinical studies, the main purpose of which is to explore the tolerability, safety, cytokinetic characteristics and RP2D and preliminary…
- Trial name
- NCT05562024
- Testing
- T cell injection targeting B7-H3 chimeric antigen receptor
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.